Share Prices & Company Research

Market News

20 May 2020 | 10:24

Arix portfolio firm Amplyx extends its series C funding

(Sharecast News) - Venture capital company Arix Bioscience noted on Wednesday that its portfolio company, Amplyx Pharmaceuticals, has closed a $53m (£43.22m) series C extension. The London-listed firm said it participated in the series C in 2017, committing $6m in two tranches.

It said $3.6m of that commitment was drawn down on close of the series C in August 2017, with the remaining $2.4m drawn down in December 2019, to complete the series C financing.

That financing had now been extended to include additional capital from new investors Pfizer and Adage Capital, on the original series C terms.

"This additional capital brings the total series C funds to over $90.0 million, which will be used to advance the clinical development of the company's two product candidates, 'fosmanogepix' and 'MAU868', for the treatment of life-threatening fungal infections and BK virus," the Arix board said in its statement.

Arix said it had retained a stake of 3.0% in Amplyx, valued at $6.4m.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 16th October 2020
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.